ATE304842T1 - Arzneizusammensetzungen enthaltend rapamycinderivate - Google Patents

Arzneizusammensetzungen enthaltend rapamycinderivate

Info

Publication number: ATE304842T1
Authority: AT; Austria
Prior art keywords: compositions containing; phosphatidylglycerol; medicinal compositions; sub; salt
Prior art date: 1996-01-19

Application number

AT02022256T

Other languages

English (en)

Inventor

Harry Tiemessen

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-19

Filing date

1997-01-20

Publication date

2005-10-15

1997-01-20 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE304842T1 publication Critical patent/ATE304842T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
239000013543 active substance Substances 0.000 abstract 2
239000000839 emulsion Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000003381 stabilizer Substances 0.000 abstract 2
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
229930186217 Glycolipid Natural products 0.000 abstract 1
ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 abstract 1
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000012141 concentrate Substances 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
239000002960 lipid emulsion Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000003960 organic solvent Substances 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
229940068196 placebo Drugs 0.000 abstract 1
239000000902 placebo Substances 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
150000003408 sphingolipids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Dispersion Chemistry (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Virology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)

AT02022256T 1996-01-19 1997-01-20 Arzneizusammensetzungen enthaltend rapamycinderivate ATE304842T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9601120.0A GB9601120D0 (en)	1996-01-19	1996-01-19	Organic compounds

Publications (1)

Publication Number	Publication Date
ATE304842T1 true ATE304842T1 (de)	2005-10-15

Family

ID=10787276

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AT02022256T ATE304842T1 (de)	1996-01-19	1997-01-20	Arzneizusammensetzungen enthaltend rapamycinderivate
AT02022257T ATE310504T1 (de)	1996-01-19	1997-01-20	Arzneizusammensetzungen enthaltend ascomycinderivate
AT05018663T ATE510532T1 (de)	1996-01-19	1997-01-20	Arzneizusammensetzungen enthaltend rapamycinderivate
AT97901563T ATE239449T1 (de)	1996-01-19	1997-01-20	(3'-desoxy-3-oxo-mebmt)1-(val)2-ciclosporin enthaltende arzneimittelemulsion

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
AT02022257T ATE310504T1 (de)	1996-01-19	1997-01-20	Arzneizusammensetzungen enthaltend ascomycinderivate
AT05018663T ATE510532T1 (de)	1996-01-19	1997-01-20	Arzneizusammensetzungen enthaltend rapamycinderivate
AT97901563T ATE239449T1 (de)	1996-01-19	1997-01-20	(3'-desoxy-3-oxo-mebmt)1-(val)2-ciclosporin enthaltende arzneimittelemulsion

Country Status (14)

Country	Link
US (2)	US6239102B1 (de)
EP (4)	EP0874621B1 (de)
JP (2)	JP4077386B2 (de)
KR (1)	KR100485146B1 (de)
AT (4)	ATE304842T1 (de)
AU (1)	AU1543497A (de)
CA (2)	CA2678707A1 (de)
DE (3)	DE69721729T2 (de)
DK (4)	DK0874621T3 (de)
ES (4)	ES2253483T3 (de)
GB (1)	GB9601120D0 (de)
HK (2)	HK1054183B (de)
PT (2)	PT1679064E (de)
WO (1)	WO1997025977A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5660858A (en) *	1996-04-03	1997-08-26	Research Triangle Pharmaceuticals	Cyclosporin emulsions
DE69736750T2 (de)	1996-07-30	2007-08-16	Novartis Ag	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US6284268B1 (en)	1997-12-10	2001-09-04	Cyclosporine Therapeutics Limited	Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19810655A1 (de) *	1998-03-12	1999-09-16	Univ Eberhard Karls	Arzneimittel mit einem Gehalt an Ciclosporin
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
TW537894B (en)	1998-05-26	2003-06-21	Novartis Ag	A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
US7265150B1 (en) *	1998-08-14	2007-09-04	Gpi Nil Holdings Inc.	Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) *	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US7063857B1 (en)	1999-04-30	2006-06-20	Sucampo Ag	Use of macrolide compounds for the treatment of dry eye
CZ20013769A3 (cs) *	1999-04-30	2002-03-13	Sucampo Ag	Činidlo pro léčbu suchého oka
WO2000067773A2 (en)	1999-05-10	2000-11-16	Novartis Ag	Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6720001B2 (en) *	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
US7473681B2 (en)	2000-10-31	2009-01-06	Pharma Mar, S.A.	Kahalalide F
CN1551767A (zh)	2001-02-19	2004-12-01	��˹��ŵ��	癌症的治疗
AU2002320407A1 (en) *	2001-07-10	2003-01-29	Trustees Of Boston University	Modified-fat nutritional products useful for preventing or treating obesity
US6641611B2 (en)	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
HRP20070058B1 (hr)	2001-10-19	2014-05-23	Isotechnika Inc.	Sinteza ciklosporinskih analoga
WO2004045578A2 (en) *	2002-11-15	2004-06-03	Novartis Ag	Drug delivery system
GB0307867D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
GB0307866D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
JP2007505932A (ja) *	2003-09-18	2007-03-15	マクサイト，インコーポレイテッド	経強膜送達
US20080311207A1 (en) *	2004-09-08	2008-12-18	Manoj Varshney	Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
GB0428151D0 (en)	2004-12-22	2005-01-26	Novartis Ag	Organic compounds
CA2597590A1 (en)	2005-02-09	2006-08-17	Macusight, Inc.	Formulations for ocular treatment
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
GB0504995D0 (en) *	2005-03-11	2005-04-20	Biotica Tech Ltd	Use of a compound
KR101478164B1 (ko)	2006-02-09	2014-12-31	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en)	2006-03-23	2012-07-19	Santen Pharmaceutical Co., Ltd.	Formulations and methods for vascular permeability-related diseases or conditions
US7883855B2 (en) *	2006-07-21	2011-02-08	Abbott Laboratories	Immunosuppressant drug extraction reagent for immunoassays
US8414909B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
WO2008063581A2 (en) *	2006-11-20	2008-05-29	Lutonix, Inc.	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
ES2393135T3 (es)	2006-12-29	2012-12-18	Abbott Laboratories	Ensayo mejorado para fármacos inmunosupresores
WO2008082984A2 (en)	2006-12-29	2008-07-10	Abbott Laboratories	Non-denaturing lysis reagent for use with capture-in-solution immunoassay
US7914999B2 (en) *	2006-12-29	2011-03-29	Abbott Laboratories	Non-denaturing lysis reagent
ES2405364T3 (es) *	2006-12-29	2013-05-30	Abbott Laboratories	Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
FR2911069B1 (fr) *	2007-01-09	2009-04-03	Physica Pharma Soc Par Actions	Composition pharmaceutique parenterale et son procede de preparation
US20080265343A1 (en) *	2007-04-26	2008-10-30	International Business Machines Corporation	Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CN102202672A (zh) *	2008-10-10	2011-09-28	达拉生物科学公司	使用穗霉素衍生物治疗或预防疼痛的方法
EP2682106A1 (de)	2012-07-03	2014-01-08	Phares Pharmaceutical Research N.V.	Verfahren zum Auflösen biologisch aktiver Verbindungen
US10172789B2 (en)	2013-01-24	2019-01-08	Palvella Therapeutics Llc	Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu)	2014-02-14	2015-08-28	Druggability Technologies Ip Holdco Jersey Ltd	Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
TWI749091B (zh)	2016-10-28	2021-12-11	法商施維雅藥廠	脂質體調配物
WO2018129364A1 (en)	2017-01-06	2018-07-12	Palvella Therapeutics Llc	Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (de)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
KR102003183B1 (ko)	2019-02-27	2019-07-24	배영진	안면마스크

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE296122C (de) *
US4707470A (en)	1985-05-17	1987-11-17	Smithkline Beckman Corporation	Polyene antibiotic emulsion formulation
CA1323306C (en)	1987-03-05	1993-10-19	Mircea C. Popescu	Pharmacological agent-lipid solution preparation
ATE95193T1 (de) *	1987-06-17	1993-10-15	Sandoz Ag	Cyclosporine und deren benutzung als arzneimittel.
JP2688235B2 (ja)	1987-09-07	1997-12-08	帝人株式会社	医薬物質含有脂肪乳剤の用時調製型キットおよび医薬物質含有脂肪乳剤の調製方法
IL88076A (en)	1987-10-28	1993-01-14	Nippon Shinyaku Co Ltd	Fat emulsions as drug carriers
AU598958B2 (en)	1987-11-12	1990-07-05	Vestar, Inc.	Improved amphotericin b liposome preparation
EP0356399A3 (de) *	1988-08-26	1991-03-20	Sandoz Ag	Substituierte 4-Azatricyclo (22.3.1.04.9) octacos-18-en-Derivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
DD295766A5 (de) *	1988-10-10	1991-11-14	Arzneimittelwerk Dresden Gmbh,De	Verfahren zur herstellung galenischer arzneiformen von ciclosporinen
JP2502719B2 (ja)	1988-12-28	1996-05-29	集合住宅用新材料・機器システム開発技術研究組合	冷暖給湯ヒ―トポンプシステム
ZA905202B (en)	1989-07-05	1991-04-24	Fujisawa Pharmaceutical Co	Aqueous liquid composition for external use
JPH03147892A (ja)	1989-11-06	1991-06-24	Mitsubishi Rayon Co Ltd	昇華性分散染料易染性樹脂組成物
ATE126803T1 (de) *	1989-11-09	1995-09-15	Sandoz Ag	Heteroatome enthaltende tricyclische verbindungen.
US5352671A (en) *	1989-11-09	1994-10-04	Sandoz Ltd.	Heteroatoms-containing tricyclic compounds
JPH04253907A (ja) *	1990-05-23	1992-09-09	Green Cross Corp:The	静脈注射用免疫抑制剤
CA2054983A1 (en)	1990-11-08	1992-05-09	Sotoo Asakura	Suspendible composition and process for preparing the same
MX9201782A (es)	1991-04-19	1992-10-01	Sandoz Ag	Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5457111A (en) *	1991-09-05	1995-10-10	Abbott Laboratories	Macrocyclic immunomodulators
ES2140419T3 (es)	1991-10-31	2000-03-01	Fujisawa Pharmaceutical Co	Preparacion de liposoma que contiene un compuesto triciclico.
GB9208712D0 (en)	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
DE59310166D1 (de)	1992-05-18	2001-05-31	Ciclomulsion Ag	Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
JPH06183970A (ja) *	1992-12-16	1994-07-05	Fujisawa Pharmaceut Co Ltd	医薬用組成物
GB2278780B (en)	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
CH686761A5 (de)	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
AU688782B2 (en) *	1993-09-30	1998-03-19	Wyeth	Rapamycin formulations for oral administration
FI100692B (fi) *	1994-05-24	1998-02-13	Leiras Oy	Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
DK0786986T3 (da) *	1994-10-26	2002-04-29	Novartis Ag	Anvendelse af en umættet fedtalkohol

1996
- 1996-01-19 GB GBGB9601120.0A patent/GB9601120D0/en active Pending
1997
- 1997-01-20 DK DK97901563T patent/DK0874621T3/da active
- 1997-01-20 KR KR10-1998-0704696A patent/KR100485146B1/ko not_active Expired - Lifetime
- 1997-01-20 DK DK02022257T patent/DK1273289T3/da active
- 1997-01-20 AT AT02022256T patent/ATE304842T1/de active
- 1997-01-20 CA CA002678707A patent/CA2678707A1/en not_active Abandoned
- 1997-01-20 AT AT02022257T patent/ATE310504T1/de active
- 1997-01-20 ES ES02022257T patent/ES2253483T3/es not_active Expired - Lifetime
- 1997-01-20 WO PCT/EP1997/000252 patent/WO1997025977A1/en not_active Ceased
- 1997-01-20 US US09/091,072 patent/US6239102B1/en not_active Ceased
- 1997-01-20 AT AT05018663T patent/ATE510532T1/de active
- 1997-01-20 DE DE69721729T patent/DE69721729T2/de not_active Expired - Lifetime
- 1997-01-20 EP EP97901563A patent/EP0874621B1/de not_active Expired - Lifetime
- 1997-01-20 ES ES97901563T patent/ES2199338T3/es not_active Expired - Lifetime
- 1997-01-20 DE DE69734253T patent/DE69734253T2/de not_active Expired - Lifetime
- 1997-01-20 DK DK02022256T patent/DK1273288T3/da active
- 1997-01-20 EP EP05018663A patent/EP1679064B1/de not_active Expired - Lifetime
- 1997-01-20 ES ES05018663T patent/ES2365734T3/es not_active Expired - Lifetime
- 1997-01-20 AT AT97901563T patent/ATE239449T1/de active
- 1997-01-20 DE DE69734742T patent/DE69734742T2/de not_active Expired - Lifetime
- 1997-01-20 PT PT05018663T patent/PT1679064E/pt unknown
- 1997-01-20 ES ES02022256T patent/ES2247245T3/es not_active Expired - Lifetime
- 1997-01-20 CA CA2240339A patent/CA2240339C/en not_active Expired - Lifetime
- 1997-01-20 AU AU15434/97A patent/AU1543497A/en not_active Abandoned
- 1997-01-20 DK DK05018663.4T patent/DK1679064T3/da active
- 1997-01-20 EP EP02022256A patent/EP1273288B1/de not_active Expired - Lifetime
- 1997-01-20 US US10/345,665 patent/USRE42014E1/en not_active Expired - Lifetime
- 1997-01-20 EP EP02022257A patent/EP1273289B1/de not_active Expired - Lifetime
- 1997-01-20 PT PT97901563T patent/PT874621E/pt unknown
1999
- 1999-02-05 HK HK03104827.8A patent/HK1054183B/en not_active IP Right Cessation
- 1999-02-05 HK HK03104828.7A patent/HK1053973B/en not_active IP Right Cessation
2003
- 2003-09-29 JP JP2003337458A patent/JP4077386B2/ja not_active Expired - Lifetime
2007
- 2007-06-19 JP JP2007161630A patent/JP2007246543A/ja active Pending

Also Published As

Publication number	Publication date
JP2004107350A (ja)	2004-04-08
EP1679064B1 (de)	2011-05-25
DK1679064T3 (da)	2011-09-12
CA2240339C (en)	2010-11-16
HK1053973B (en)	2006-09-29
JP4077386B2 (ja)	2008-04-16
EP1273289A1 (de)	2003-01-08
EP1679064A2 (de)	2006-07-12
HK1054183A1 (en)	2003-11-21
PT874621E (pt)	2003-09-30
DK0874621T3 (da)	2003-09-01
EP1273288A1 (de)	2003-01-08
DE69721729T2 (de)	2003-12-11
JP2000503655A (ja)	2000-03-28
CA2240339A1 (en)	1997-07-24
ES2247245T3 (es)	2006-03-01
EP1273289B1 (de)	2005-11-23
PT1679064E (pt)	2011-07-25
ATE510532T1 (de)	2011-06-15
CA2678707A1 (en)	1997-07-24
ATE310504T1 (de)	2005-12-15
KR100485146B1 (ko)	2005-10-12
ES2365734T3 (es)	2011-10-10
HK1054183B (en)	2006-07-28
JP2007246543A (ja)	2007-09-27
AU1543497A (en)	1997-08-11
EP0874621A1 (de)	1998-11-04
DE69734253T2 (de)	2006-07-06
ATE239449T1 (de)	2003-05-15
DK1273289T3 (da)	2006-03-20
EP1679064A3 (de)	2009-10-07
JP3763581B2 (ja)	2006-04-05
HK1015277A1 (en)	1999-10-15
DE69734742D1 (de)	2005-12-29
EP0874621B1 (de)	2003-05-07
USRE42014E1 (en)	2010-12-28
DE69721729D1 (de)	2003-06-12
US6239102B1 (en)	2001-05-29
EP1273288B1 (de)	2005-09-21
DE69734742T2 (de)	2006-07-27
DK1273288T3 (da)	2005-11-21
HK1053973A1 (en)	2003-11-14
DE69734253D1 (de)	2006-02-02
GB9601120D0 (en)	1996-03-20
KR19990076603A (ko)	1999-10-15
ES2253483T3 (es)	2006-06-01
ES2199338T3 (es)	2004-02-16
WO1997025977A1 (en)	1997-07-24

Legal Events

Date

Code

Title

Description

2006-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1273288

Country of ref document: EP

Publication	Publication Date	Title
ATE510532T1 (de)	2011-06-15	Arzneizusammensetzungen enthaltend rapamycinderivate
US5059593A (en)	1991-10-22	Pour-on formulations which are active against ticks
KR950007859A (ko)	1995-04-15	경구 투여용 라파마이신 제형
KR970706021A (ko)	1997-11-03	N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
BE900345A (fr)	1984-12-03	Composition pharmaceutique ophtalmiques a base d'un derive d'acide phenylacetique.
DK0525307T3 (da)	1996-04-01	Stabile præparater til parenteral indgivelse og deres anvendelse
DK163182C (da)	1992-06-22	Dialkylaminoalkoxybenzylalkoholderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og fremgangsmaade til fremstilling deraf
RU97118134A (ru)	1999-07-10	Новые противовирусные гомокарбоциклические нуклеозидные производные замещенных пиримидиндионов, способы их получения и композиции, содержащие их в качестве активных ингредиентов
KR930703251A (ko)	1993-11-29	에어로졸 제제
PL255643A1 (en)	1987-01-12	Method of obtaining 2-pyridinothiole derivatives
US5034420A (en)	1991-07-23	Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant
ATE23150T1 (de)	1986-11-15	Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR920701149A (ko)	1992-08-11	15-데옥시프로스타글란딘 유도체
KR910016252A (ko)	1991-11-05	살충 및 살질균제
CY1531A (en)	1990-11-16	Compositions and method for stabilization of anthralin
KR960703600A (ko)	1996-08-31	활성제로서 이소플라본 유도체 또는 그것의 염을 포함하는 제약학적인 조성물(pharmaceutical compositions containing as active agent isoflavone derivatives or salts thereof)
KR880013874A (ko)	1988-12-22	카르복실산 에스테르, 그의 제조방법 및 그것을 유효 성분으로 함유하는 살충제
PT84635A (en)	1987-05-01	Process for the preparation of stable injectable compositions containing 4-amino-5-chloro-n-]2-(diethylamino) ethyl"-2-](substituted) alkoxy" benzamide antiemetic agents